DURHAM – Shattuck Labs, a life science startup focusing on development of new treatments for cancer and autoimmune disease, is going public today and expects to raise $202 million the process.
The company in June closed on $118 million in new financing and secured Durham-based Hatteras Venture Partners as a backer.
In an announcement made late Thursday, Shattuck said shares would begin trading today on the Nasdaq under the symbol “STTK.”
Shares were priced at $17.
Some 11,882,352 shares were issued with underwriters having the option to purchase another 1.8 million shares.
The company has offices in Durham and Austin, Texas.
Original Article Source: WRAL TechWire